A1 cont.

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, R_{10}, and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$, or



n is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

Remarks

The USPTO has informed Applicants that this continuation application was filed with page 220 missing. Page 220 consists of part of claim 7. This Preliminary Amendment is provided to correct the omission of that portion of claim 7.

Support for this amendment may be found in the specification beginning on line 1 of page 78 and continuing to line 6 of page 79.

A Version With Markings To Show Changes Made is attached. For the Examiner's convenience, a copy of page 220 is attached. Applicants request that the portion of claim 7 added by this Amendment be inserted as page 220, to provide the proper sequential numbering of the pages of the specification.

Applicants do not believe that a fee is due herewith, but if a fee should be due it may be charged to Deposit Acct. No. 01-1425.

Joseph M. Mazzarese

Reg. No. **32,803**

American Home Products Corporation
Patent Law Department
Five Giralda Farms
Madison, NJ 07940-0874
Tel. No. (973) 683-**2150**

Version With Markings To Show Changes Made

--7. A compound of Claim 2 having the formula:



or

wherein:

R_1 is selected from Halogen, $-NH_2$, -O-phenyl, benzyl, -O-benzyl, -N-benzyl, -N-benzyl-O-phenyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH; or R_1 is or a moiety of the formulae:



R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-CF_3$, or -OH;

R_7 is selected from $-(CH_2)_n$-COOH, $-(CH_2)_n$-N-(C_1-C_6 alkyl)$_2$, $-(CH_2)_n$-NH-(C_1-C_6 alkyl), $-CF_3$, C_1-C_6 alkyl, C_3-C_5 cycloalkyl, C_1-C_6 alkoxy, -NH-(C_1-C_6 alkyl), -N-(C_1-C_6

alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, phenyl, -O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NO_2, -CF_3, or -OH;

n is an integer from 0 to 3;

R_3 is selected from H, -CF_3, -COOH, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, -C_1-C_6 alkyl-C_3-C_{10} cycloalkyl, -CHO, halogen, or a moiety of the formulae:







wherein n is independently selected in each appearance as an integer from 0 to 3, preferably 0 to 2, more preferably 0 to 1, Y is C_1-C_6 alkyl, C_3-C_5 cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl, morpholinyl, pyrrolidinyl, or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH_2, -NO_2 or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O, preferably S or O;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, -$(CH_2)_n$-C_3-C_6 cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or the groups of:

a) a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2;

R_5 is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, -CH_2-phenyl-C(O)-benzothiazole,

$(CH_2)_n$-CH=CH-COOH,



,



, ,



n is an integer from 0 to 3;

R_8 is selected from H, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, $-(CH_2)_n$-C(O)-NH_2,

n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-CF_3$, -OH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$;
n is an integer from 0 to 3;

R_{10} is selected from the group of H, halogen, $-CF_3$, -OH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-C_6 alkyl, -O-C_1-C_6 alkyl, $-NH(C_1$-C_6 alkyl), $-N(C_1$-C_6 alkyl$)_2$,


,


,



,



or



;

n is an integer from 0 to 3;

R_{11} is selected from H, C_1-C_6 lower alkyl, $-CF_3$, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, or


;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, R_{10}, and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$, or


;

n is an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.--